drugset / Trial / NCT01903460

Safety and Efficacy Study of LUM001 in the Treatment of Cholestatic Liver Disease in Patients With Alagille Syndrome

NCT01903460

Phase 2 Completed 20 enrolled Mirum Pharmaceuticals, Inc.
RandomizedParallel-groupTriple-blindTreatment

Summary

The study is a randomized, double-blind, placebo-controlled study to evaluate the safety and tolerability of LUM001. Efficacy will be assessed by evaluating the effect of LUM001 versus placebo on the biochemical markers and pruritus associated with Alagille Syndrome.

Timeline

Start
2013-08
Primary completion
2015-02
Completion
2015-03

Drugs

EvaluationDrugModalityDoseRoute
Subject Maralixibat Small molecule Oral

Indications